The Molecular Mechanism for Differentiation Therapy of Malignant Glioma

Wenbo Zhu,Guangmei Y
DOI: https://doi.org/10.5772/21215
2011-01-01
Abstract:IntroductionGliomas are the most common malignant cancer affecting the CNS, accounting for 60% of primary brain tumors (DeAngelis, 2001; Yiu&He, 2006).The majority of gliomas in adults are highly malignant with a poor prognosis, in particular with high-grade tumors such as glioblastoma multiforme.Current therapy with surgery, radiation, and chemotherapy rarely, if ever, cures the disease and infrequently prolongs life for 1 year (Curran et al., 1993;Bao et al., 2006).Additional considerations focus on developing novel modalities to increase anti-glioma effects and decrease side-effects.Differentiation therapy, using agents that modify cancer cell differentiation, has shown promise in the spectrum of agents used against tumors (Leszczyniecka et al., 2001).Wang and Chen demonstrated the clinical application for differentiation therapy by introducing all-trans-retinoic acid to clinical use for the treatment of acute promyelocytic leukemia (APL) (Huang et al., 1988; Wang&Chen, 2000).Notably, the inorganic toxicant arsenic trioxide (As2O3), a well known environmental carcinogen, has been also proven to be an effective drug in the treatment of APL patients by triggering apoptosis and differentiation of APL cells in a dose-dependent manner (Shen et al., 1997;Kinjo et al., 2000).Such excellent effects, however, were not reproduced in other hematological and, particularly, solid tumors.Differentiation agents for malignant gliomas remain a real challenge.In this chapter, we base on our research and mainly discuss proteins or molecules capable of inducing differentiation via targeting cAMP/cAMP-dependent protein kinase A (PKA) signal pathway and crucial factors such as glycogen synthase kinase-3 (GSK-3 ) and hypoxia-inducible factor-1 (HIF-1 ) determining the efficiency of these drugs.Although agents for differentiation therapy have wide application prospect, their real therapeutic potentiality remains to be further realized. The molecular mechanism for differentiation therapy of malignant glioma2.1 cAMP/PKA signaling activators induce malignant glioma cell differentiation cAMP/PKA signaling has been reported to play important roles in multiple physiological processes, including growth, differentiation, gene regulation, and apoptosis (Walsh&Van Patten, 1994).Disruption of the PKA catalytic subunit causes destabilization of the diploid cell cycle, and the cells start meiosis under conditions repressive for wild-type meiosis (Maeda et al., 1994).Ample evidences indicate that cAMP-elevating stimuli such as Nwww.intechopen.com
What problem does this paper attempt to address?